PXT3003 van Pharnext onder de aandacht op bijeenkomst Neuromuscular & Electrodiagnostic Medicine (AANEM) 2017
PARIJS–(BUSINESS WIRE)–Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), een biofarmaceutisch bedrijf met een vernieuwende benadering van geneesmiddelen door reeds bekende medicijnen te combineren en te herpositioneren, heeft vandaag bekendgemaakt dat gegevens met betrekking tot PXT3003 – zijn belangrijkste PLEODRUG™ – als geneesmiddel tegen de ziekte van of Charcot-Matrie-tooth type 1A (CMT1A) worden gepresenteerd in een postersessie op de jaarlijkse bijeenkomst van AANEM 2017, dat van 13 tot 16 september plaatsvindt in Phoenix, Arizona.
| Datum & Tijd | Titel | |
|
14-15 september |
Poster #90: “Een in meerdere centra, dubbelblind uitgevoerd Fase 3-onderzoek met placebocontrole (PLEOCMT) van een vaste combinatie van baclofen, naltrexone and sorbitol (PXT3003) voor de behandeling van CMT1A” , S.Attarian et al. |
Pharnext’s PXT3003 Featured at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2017 Annual Meeting |
||||||||
|
PARIS–(BUSINESS WIRE)– Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that data related to PXT3003, the Company’s lead PLEODRUG™, in development for the treatment of Charcot-Matrie-tooth type 1A (CMT1A) disease will be presented in a poster viewing session at the AANEM 2017 Annual Meeting, September 13-16, in Phoenix, Arizona, U.S. Details are as follow:
The abstract is available online at : http://www.aanem.org/Meetings/Annual-Meeting/Abstracts About PXT3003 PXT3003, Pharnext’s lead PLEODRUG™ in development for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), is a novel, synergistic, low-dose combination of baclofen, naltrexone, and D-sorbitol formulated as an oral solution given twice-daily. PXT3003 has multiple main mechanisms of action: a synergistic inhibition of PMP22 gene overexpression associated with myelination improvement, direct nerve protection and additional positive effects on other cellular types: muscle cells, neuromuscular junctions and immune cells. PXT3003 obtained positive results in a Phase II clinical trial in 80 adult patients with CMT1A. In 2014, the EMA and FDA granted orphan drug designation to PXT3003 for the treatment of CMT1A in adults. An international pivotal Phase III trial (PLEO-CMT) in over 300 adult patients with CMT1A is now underway at 30 sites across Europe, the U.S. and Canada. About Pharnext Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287). View source version on businesswire.com: http://www.businesswire.com/news/home/20170907006130/en/ Contacts Pharnext |
||||||||